taurocholic acid has been researched along with Angiogenesis, Pathologic in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hattori, T; Mukaisho, K; Saito, S; Sato, S; Sugihara, H; Yamamoto, G; Yamamoto, H | 1 |
| Al-Hilal, TA; Alam, F; Byun, Y; Chung, SW; Kim, HS; Lee, DS; Mahmud, F; Park, J; Seo, D | 1 |
| Al-Hilal, TA; Bae, SM; Byun, Y; Chung, SW; Kim, IS; Kim, JK; Kim, SY; Lee, CK; Lee, M | 1 |
| Byun, Y; Chung, SW; Kim, JY; Kim, SY | 1 |
| Bae, SM; Byun, Y; Chung, SW; Jeon, OC; Jin, S; Kim, IS; Kim, SK; Kim, SY; Kim, YS; Lee, E; Lee, M; Moon, HT; Park, RW | 1 |
| Byun, Y; Choi, HW; Chung, SW; Kim, CW; Kim, JY; Kim, K; Kim, S; Kim, SY; Kwon, IC; Oh, YK; Park, J; Shim, G; Yang, VC | 1 |
| Bae, SM; Byun, Y; Choe, H; Chung, SW; Jeon, OC; Kim, HS; Kim, SY; Lee, BS; Lee, HS; Lee, M; Park, J; Park, RW | 1 |
7 other study(ies) available for taurocholic acid and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Continuous taurocholic acid exposure promotes esophageal squamous cell carcinoma progression due to reduced cell loss resulting from enhanced vascular development.
Topics: Animals; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; Disease Progression; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Flow Cytometry; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Rats; RNA, Messenger; Taurocholic Acid; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Heparin, Low-Molecular-Weight; Humans; Male; Mice, Inbred C3H; Mice, Nude; Nanostructures; Neoplasms; Neovascularization, Pathologic; Polyethylene Glycols; Protamines; Rats, Sprague-Dawley; Taurocholic Acid; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
Topics: Angiogenesis Inhibitors; Animals; Cell Line; Chemotaxis; Coculture Techniques; Collagen; Contrast Media; Drug Combinations; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Heparin, Low-Molecular-Weight; Human Umbilical Vein Endothelial Cells; Humans; Kinetics; Laminin; Magnetic Resonance Imaging; Male; Mice, Inbred BALB C; Neoplasms; Neovascularization, Pathologic; Pericytes; Proteoglycans; Proto-Oncogene Proteins c-sis; Signal Transduction; Taurocholic Acid; Vascular Endothelial Growth Factor A | 2015 |
Enhanced Anti-Angiogenic Effect of Low Molecular Weight Heparin-Bile Acid Conjugates by Co-Administration of a Selective COX-2 Inhibitor.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cell Hypoxia; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heparin, Low-Molecular-Weight; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Inbred Strains; Neovascularization, Pathologic; Taurocholic Acid; Xenograft Model Antitumor Assays | 2015 |
Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor.
Topics: Angiogenesis Inhibitors; Animals; Cells, Cultured; Circular Dichroism; Collagen; Drug Combinations; Endothelium, Vascular; Heparin; Heparin, Low-Molecular-Weight; Humans; Laminin; Male; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Neovascularization, Pathologic; Peptides; Phosphorylation; Proteoglycans; Taurocholic Acid; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2009 |
Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex.
Topics: Animals; Antineoplastic Agents; Cations; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Electrophoretic Mobility Shift Assay; Heparin; Hydroxamic Acids; Injections, Intravenous; Liposomes; Mice; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Serum; Taurocholic Acid; Time Factors; Tissue Distribution; Vorinostat | 2012 |
Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge.
Topics: Angiogenesis Inhibitors; Anions; Anticoagulants; Antithrombin III; Cell Line, Tumor; Heparin, Low-Molecular-Weight; HT29 Cells; Humans; Neovascularization, Pathologic; Oligosaccharides; Taurocholic Acid; Vascular Endothelial Growth Factor A | 2012 |